Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops
Rho iso-alpha-acids (RIAA) is a modified extract from the flower cone of hops ( Humulus lupulus L.). The safety profile and anti-inflammatory activity of RIAA was assessed using in vitro models and clinical biomarkers. This study suggests that RIAA is an alternative to NSAIDs with an expected reduct...
Saved in:
| Published in | Phytochemistry (Oxford) Vol. 69; no. 7; pp. 1534 - 1547 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Amsterdam
Elsevier Ltd
01.05.2008
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0031-9422 1873-3700 |
| DOI | 10.1016/j.phytochem.2008.02.001 |
Cover
Loading…
| Abstract | Rho
iso-alpha-acids (RIAA) is a modified extract from the flower cone of hops (
Humulus lupulus L.). The safety profile and anti-inflammatory activity of RIAA was assessed using
in vitro models and clinical biomarkers. This study suggests that RIAA is an alternative to NSAIDs with an expected reduction in adverse events.
A defined mixture of rho
iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated PGE
2 formation with >200-fold selectivity of COX-2 (IC
50
=
1.3
μg/ml) over COX-1 (IC
50
>
289
μg/ml). This occurred only when RIAA was added prior to, but not post, LPS stimulation. Consistent with this observation, RIAA produced no physiologically relevant, direct inhibition of COX-1 or COX-2 peroxidase activity. This suggests that RIAA inhibits inducible but not constitutive COX-2. In support, we found RIAA showed minimal PGE
2 inhibition (IC
50
=
21
μg/ml) relative to celecoxib (IC
50
=
0.024
μg/ml), aspirin (IC
50
=
0.52
μg/ml) or ibuprofen (IC
50
=
0.57
μg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively. Taken together these results predict RIAA may have lower potential for gastrointestinal and cardiovascular toxicity observed with COX enzyme inhibitors. Following confirmation of bioavailable RIAA administered orally, gastrointestinal safety was assessed using the fecal calprotectin biomarker in a 14-day human clinical study; RIAA (900
mg/day) produced no change compared to naproxen (1000
mg/day), which increased fecal calprotectin 200%. Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000
mg) did not reduce PGI-M or affect the urinary PGI-M/TXB
2 ratio. Drug interaction potential was evaluated against six major CYPs; of relevance, RIAA inhibited CYP2C9. Toxicity was assessed in a 21-day oral, mouse subchronic toxicity study where no dose dependent histopathological effects were noted. Clinically, RIAA (1000
mg/day) produced a 54% reduction in WOMAC Global scores in a 6-week, open-label trial of human subjects exhibiting knee osteoarthritis. |
|---|---|
| AbstractList | A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated PGE2 formation with >200-fold selectivity of COX-2 (IC50 = 1.3 μg/ml) over COX-1 (IC50 > 289 μg/ml). This occurred only when RIAA was added prior to, but not post, LPS stimulation. Consistent with this observation, RIAA produced no physiologically relevant, direct inhibition of COX-1 or COX-2 peroxidase activity. This suggests that RIAA inhibits inducible but not constitutive COX-2. In support, we found RIAA showed minimal PGE2 inhibition (IC50 = 21 μg/ml) relative to celecoxib (IC50 = 0.024 μg/ml), aspirin (IC50 = 0.52 μg/ml) or ibuprofen (IC50 = 0.57 μg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively. Taken together these results predict RIAA may have lower potential for gastrointestinal and cardiovascular toxicity observed with COX enzyme inhibitors. Following confirmation of bioavailable RIAA administered orally, gastrointestinal safety was assessed using the fecal calprotectin biomarker in a 14-day human clinical study; RIAA (900 mg/day) produced no change compared to naproxen (1000 mg/day), which increased fecal calprotectin 200%. Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000 mg) did not reduce PGI-M or affect the urinary PGI-M/TXB2 ratio. Drug interaction potential was evaluated against six major CYPs; of relevance, RIAA inhibited CYP2C9. Toxicity was assessed in a 21-day oral, mouse subchronic toxicity study where no dose dependent histopathological effects were noted. Clinically, RIAA (1000 mg/day) produced a 54% reduction in WOMAC Global scores in a 6-week, open-label trial of human subjects exhibiting knee osteoarthritis. Rho iso-alpha-acids (RIAA) is a modified extract from the flower cone of hops ( Humulus lupulus L.). The safety profile and anti-inflammatory activity of RIAA was assessed using in vitro models and clinical biomarkers. This study suggests that RIAA is an alternative to NSAIDs with an expected reduction in adverse events. A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated PGE 2 formation with >200-fold selectivity of COX-2 (IC 50 = 1.3 μg/ml) over COX-1 (IC 50 > 289 μg/ml). This occurred only when RIAA was added prior to, but not post, LPS stimulation. Consistent with this observation, RIAA produced no physiologically relevant, direct inhibition of COX-1 or COX-2 peroxidase activity. This suggests that RIAA inhibits inducible but not constitutive COX-2. In support, we found RIAA showed minimal PGE 2 inhibition (IC 50 = 21 μg/ml) relative to celecoxib (IC 50 = 0.024 μg/ml), aspirin (IC 50 = 0.52 μg/ml) or ibuprofen (IC 50 = 0.57 μg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively. Taken together these results predict RIAA may have lower potential for gastrointestinal and cardiovascular toxicity observed with COX enzyme inhibitors. Following confirmation of bioavailable RIAA administered orally, gastrointestinal safety was assessed using the fecal calprotectin biomarker in a 14-day human clinical study; RIAA (900 mg/day) produced no change compared to naproxen (1000 mg/day), which increased fecal calprotectin 200%. Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000 mg) did not reduce PGI-M or affect the urinary PGI-M/TXB 2 ratio. Drug interaction potential was evaluated against six major CYPs; of relevance, RIAA inhibited CYP2C9. Toxicity was assessed in a 21-day oral, mouse subchronic toxicity study where no dose dependent histopathological effects were noted. Clinically, RIAA (1000 mg/day) produced a 54% reduction in WOMAC Global scores in a 6-week, open-label trial of human subjects exhibiting knee osteoarthritis. A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml). This occurred only when RIAA was added prior to, but not post, LPS stimulation. Consistent with this observation, RIAA produced no physiologically relevant, direct inhibition of COX-1 or COX-2 peroxidase activity. This suggests that RIAA inhibits inducible but not constitutive COX-2. In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively. Taken together these results predict RIAA may have lower potential for gastrointestinal and cardiovascular toxicity observed with COX enzyme inhibitors. Following confirmation of bioavailable RIAA administered orally, gastrointestinal safety was assessed using the fecal calprotectin biomarker in a 14-day human clinical study; RIAA (900 mg/day) produced no change compared to naproxen (1000 mg/day), which increased fecal calprotectin 200%. Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000 mg) did not reduce PGI-M or affect the urinary PGI-M/TXB(2) ratio. Drug interaction potential was evaluated against six major CYPs; of relevance, RIAA inhibited CYP2C9. Toxicity was assessed in a 21-day oral, mouse subchronic toxicity study where no dose dependent histopathological effects were noted. Clinically, RIAA (1000 mg/day) produced a 54% reduction in WOMAC Global scores in a 6-week, open-label trial of human subjects exhibiting knee osteoarthritis. A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml). This occurred only when RIAA was added prior to, but not post, LPS stimulation. Consistent with this observation, RIAA produced no physiologically relevant, direct inhibition of COX-1 or COX-2 peroxidase activity. This suggests that RIAA inhibits inducible but not constitutive COX-2. In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively. Taken together these results predict RIAA may have lower potential for gastrointestinal and cardiovascular toxicity observed with COX enzyme inhibitors. Following confirmation of bioavailable RIAA administered orally, gastrointestinal safety was assessed using the fecal calprotectin biomarker in a 14-day human clinical study; RIAA (900 mg/day) produced no change compared to naproxen (1000 mg/day), which increased fecal calprotectin 200%. Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000 mg) did not reduce PGI-M or affect the urinary PGI-M/TXB(2) ratio. Drug interaction potential was evaluated against six major CYPs; of relevance, RIAA inhibited CYP2C9. Toxicity was assessed in a 21-day oral, mouse subchronic toxicity study where no dose dependent histopathological effects were noted. Clinically, RIAA (1000 mg/day) produced a 54% reduction in WOMAC Global scores in a 6-week, open-label trial of human subjects exhibiting knee osteoarthritis.A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml). This occurred only when RIAA was added prior to, but not post, LPS stimulation. Consistent with this observation, RIAA produced no physiologically relevant, direct inhibition of COX-1 or COX-2 peroxidase activity. This suggests that RIAA inhibits inducible but not constitutive COX-2. In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively. Taken together these results predict RIAA may have lower potential for gastrointestinal and cardiovascular toxicity observed with COX enzyme inhibitors. Following confirmation of bioavailable RIAA administered orally, gastrointestinal safety was assessed using the fecal calprotectin biomarker in a 14-day human clinical study; RIAA (900 mg/day) produced no change compared to naproxen (1000 mg/day), which increased fecal calprotectin 200%. Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000 mg) did not reduce PGI-M or affect the urinary PGI-M/TXB(2) ratio. Drug interaction potential was evaluated against six major CYPs; of relevance, RIAA inhibited CYP2C9. Toxicity was assessed in a 21-day oral, mouse subchronic toxicity study where no dose dependent histopathological effects were noted. Clinically, RIAA (1000 mg/day) produced a 54% reduction in WOMAC Global scores in a 6-week, open-label trial of human subjects exhibiting knee osteoarthritis. |
| Author | Hall, Amy J. Babish, John G. Tripp, Matthew L. Carroll, Brian J. Lerman, Robert H. Darland, Gary K. Konda, Veera Reedy Bland, Jeffery S. |
| Author_xml | – sequence: 1 givenname: Amy J. surname: Hall fullname: Hall, Amy J. email: amyhall@metagenics.com organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA – sequence: 2 givenname: John G. surname: Babish fullname: Babish, John G. organization: MetaProteomics, 30 Brown Road, Ithaca, NY 14850, USA – sequence: 3 givenname: Gary K. surname: Darland fullname: Darland, Gary K. organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA – sequence: 4 givenname: Brian J. surname: Carroll fullname: Carroll, Brian J. organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA – sequence: 5 givenname: Veera Reedy surname: Konda fullname: Konda, Veera Reedy organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA – sequence: 6 givenname: Robert H. surname: Lerman fullname: Lerman, Robert H. organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA – sequence: 7 givenname: Jeffery S. surname: Bland fullname: Bland, Jeffery S. organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA – sequence: 8 givenname: Matthew L. surname: Tripp fullname: Tripp, Matthew L. organization: Metagenics/MetaProteomics Nutrigenomics Research Center, 9770 44th Avenue, Gig Harbor, WA 98332, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20337619$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18358504$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9v1DAQxS1URLeFr0BzgRNZxk7sJAcOVQUUqRJIpWdr4j_EqyQOtrdSvn0T7bIHLnuwRrJ_78143hW5GP1oCLmhsKVAxefddurm5FVnhi0DqLfAtgD0FdnQuiryogK4IBuAguZNydgluYpxBwCcC_GGXNK64DWHckN-PaI1af6UGWudQjVnOOrlJJe70fY4DJh8WG5Vcs8uzZm3Weh85qLPsZ86zFE5HTMb_JB1fopvyWuLfTTvjvWaPH37-vvuPn_4-f3H3e1DrkpeplyD1QUYjVbXJS0o542wQhsDitbY1miFqFhJsVKiEmVrBG8VbZWqbdtw2xTX5OPBdwr-797EJAcXlel7HI3fRykaypqmLM6CZSWaSrDV8f0R3LeD0XIKbsAwy3_LWoAPRwCjwt4GHJWLJ45BUVSCrkZfDpwKPsZgrFQuYXJ-TAFdLynINUS5k6cQ5RqiBCaXEBd99Z_-NMpZ5c1BadFL_BOW6Z4e2fKwMA3jbP3D7YEwSzbPzgQZlTOjMtoFo5LU3p3t8gIo_8VW |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0033858 crossref_primary_10_1021_jf300018s crossref_primary_10_1021_jf904079h crossref_primary_10_1039_c1fo10009b crossref_primary_10_3390_molecules26040954 crossref_primary_10_1155_2010_467316 crossref_primary_10_1021_np800740m crossref_primary_10_3390_foods13244155 crossref_primary_10_1007_s00253_021_11329_4 crossref_primary_10_1080_01635581_2015_1032429 crossref_primary_10_1016_j_forsciint_2015_01_039 crossref_primary_10_1016_j_phanu_2015_03_001 crossref_primary_10_1094_ASBCJ_2014_0629_01 crossref_primary_10_1007_s11101_018_9584_y crossref_primary_10_3389_fpls_2021_589783 crossref_primary_10_1016_j_phytol_2009_10_006 crossref_primary_10_1021_acs_jafc_9b03780 crossref_primary_10_1016_j_jep_2013_01_036 crossref_primary_10_1016_j_jff_2022_105035 crossref_primary_10_1007_s00774_009_0141_z crossref_primary_10_1016_j_jff_2022_105099 crossref_primary_10_1016_j_nutres_2011_03_016 crossref_primary_10_1038_s41374_018_0112_x crossref_primary_10_1055_a_2103_3230 crossref_primary_10_1093_jat_bku038 crossref_primary_10_2174_1570193X16666190723112623 crossref_primary_10_1155_2016_9747863 crossref_primary_10_1080_01635581_2013_850963 crossref_primary_10_1016_j_jep_2015_04_036 crossref_primary_10_1002_jssc_201101109 crossref_primary_10_1590_0001_3765202220191339 crossref_primary_10_1111_1541_4337_12201 crossref_primary_10_3390_pr10030517 crossref_primary_10_1002_cbdv_202100966 crossref_primary_10_1007_s11240_023_02462_1 crossref_primary_10_1016_j_atherosclerosis_2012_05_004 crossref_primary_10_1002_ejoc_201000704 |
| Cites_doi | 10.1056/NEJMoa050330 10.1002/ptr.1709 10.1161/hh2001.098351 10.1136/gut.45.3.362 10.17660/ActaHortic.2005.668.28 10.1159/000046212 10.1073/pnas.89.16.7384 10.1029/2003EO200008 10.1161/CIRCULATIONAHA.106.636746 10.1001/jama.296.13.jrv60011 10.3109/00365529609006407 10.1056/NEJM200011233432103 10.1016/j.plefa.2006.04.006 10.1016/S0021-9258(19)36629-3 10.1056/NEJMoa050493 10.1136/gut.2005.080754 10.1073/pnas.96.1.272 10.1001/archinte.165.10.1095 10.1073/pnas.162468699 10.1139/Y07-055 10.1073/pnas.93.19.10417 10.1002/mnfr.200500027 10.1097/00054725-200606000-00013 10.1002/mrc.1234 10.1016/S0014-5793(99)01727-5 10.1124/mi.3.4.194 10.1053/gast.2003.50054 10.1111/j.1742-7843.2006.pto_302.x 10.1515/DMDI.2006.21.3-4.163 10.1097/01.mco.0000214565.67439.83 10.1016/j.prostaglandins.2006.05.019 10.1016/j.clpt.2005.09.014 10.1146/annurev.pharmtox.38.1.97 10.1172/JCI27291 10.1046/j.1440-1746.2003.03014.x 10.1016/S0301-0082(00)00063-0 10.1074/jbc.274.5.3103 10.1042/bj20030969 10.1096/fasebj.12.12.1063 10.4049/jimmunol.163.10.5617 |
| ContentType | Journal Article |
| Copyright | 2008 Elsevier Ltd 2008 INIST-CNRS |
| Copyright_xml | – notice: 2008 Elsevier Ltd – notice: 2008 INIST-CNRS |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7S9 L.6 7X8 |
| DOI | 10.1016/j.phytochem.2008.02.001 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AGRICOLA MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Botany Chemistry |
| EISSN | 1873-3700 |
| EndPage | 1547 |
| ExternalDocumentID | 18358504 20337619 10_1016_j_phytochem_2008_02_001 US201300892524 S0031942208000757 |
| Genre | Clinical Trial Journal Article |
| GroupedDBID | --- --K --M -~X .~1 0R~ 123 1B1 1RT 1~. 1~5 29O 4.4 457 4G. 53G 5VS 7-5 71M 8P~ 9JM 9JN AABNK AABVA AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALCJ AALRI AAOAW AAQFI AAQXK AARLI AATCM AATLK AAXUO ABFNM ABGRD ABGSF ABJNI ABMAC ABUDA ABXDB ABYKQ ABZDS ACDAQ ACGFS ACIUM ACNCT ACNNM ACRLP ADBBV ADECG ADEZE ADMUD ADQTV ADUVX AEBSH AEHWI AEKER AENEX AEQOU AFKWA AFTJW AFXIZ AFZHZ AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJSZI ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CBWCG CS3 D0L DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FLBIZ FNPLU FYGXN G-2 G-Q GBLVA HLV HLW HMS HMT HVGLF HZ~ H~9 IHE J1W K-O KOM LW9 LX3 M2Z M34 M41 MO0 MVM N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAB SBG SCB SCC SCU SDF SDG SDP SES SEW SOC SPC SPCBC SPT SSA SSK SSP SSU SSZ T5K TN5 TWZ WH7 WUQ XOL Y6R YK3 ZKB ~02 ~G- ~KM ABPIF ABPTK FBQ AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO ADXHL AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH EFKBS IQODW CGR CUY CVF ECM EIF NPM 7S9 L.6 7X8 |
| ID | FETCH-LOGICAL-c454t-d0fd30edafd841315596f6dee0c18ab8af667241a7c6764be65bc1bcc8fb95f93 |
| IEDL.DBID | .~1 |
| ISSN | 0031-9422 |
| IngestDate | Fri Sep 05 12:30:36 EDT 2025 Fri Sep 05 08:04:29 EDT 2025 Mon Jul 21 06:05:29 EDT 2025 Mon Jul 21 09:13:45 EDT 2025 Thu Apr 24 23:06:29 EDT 2025 Tue Jul 01 00:05:27 EDT 2025 Wed Dec 27 19:07:42 EST 2023 Fri Feb 23 02:28:31 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Cyclooxygenase Humulus lupulus L Knee osteoarthritis Prostaglandin Rho iso-alpha-acids NSAID Hops PGE 2 Cannabidaceae Calprotectin Anti-inflammatory Prostaglandin-endoperoxide synthase Toxicity Stimulation Reduction Dicotyledones Angiospermae Peroxidase Inhibition Human PGE2 Enzyme Interaction Rodentia Antiinflammatory agent Hop Enzyme inhibitor Vertebrata Mammalia Peroxidases Mouse Spermatophyta Models Oxidoreductases |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c454t-d0fd30edafd841315596f6dee0c18ab8af667241a7c6764be65bc1bcc8fb95f93 |
| Notes | http://dx.doi.org/10.1016/j.phytochem.2008.02.001 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 18358504 |
| PQID | 47697629 |
| PQPubID | 24069 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_69129943 proquest_miscellaneous_47697629 pubmed_primary_18358504 pascalfrancis_primary_20337619 crossref_citationtrail_10_1016_j_phytochem_2008_02_001 crossref_primary_10_1016_j_phytochem_2008_02_001 fao_agris_US201300892524 elsevier_sciencedirect_doi_10_1016_j_phytochem_2008_02_001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-05-01 |
| PublicationDateYYYYMMDD | 2008-05-01 |
| PublicationDate_xml | – month: 05 year: 2008 text: 2008-05-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Amsterdam |
| PublicationPlace_xml | – name: Amsterdam – name: England |
| PublicationTitle | Phytochemistry (Oxford) |
| PublicationTitleAlternate | Phytochemistry |
| PublicationYear | 2008 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Kramer (bib24) 1986; 19 Brater, Harris, Redfern, Gertz (bib5) 2001; 21 Topper, Cai, Falb, Gimbrone (bib41) 1996; 93 Nussmeier, Whelton, Brown, Langford, Hoeft, Parlow, Boyce, Verburg (bib35) 2005; 352 Anonymous, 2003. Tripp, M., Babish, J., Darland, G., Lerman, R., Lukaczer, D., Schiltz, B., Bland, J., 2004. Hop and modified hop extracts have potent in vitro anti-inflammatory properties. In: Proceedings of the First ISHS International Humulus Symposium, Corvallis, OR, USA. Solomon, Pfeffer, McMurray, Fowler, Finn, Levin, Eagle, Hawk, Lechuga, Zauber, Bertagnolli, Arber, Wittes (bib39) 2006; 114 Vanegas, Schaible (bib44) 2001; 64 Capone, Tacconelli, Di Francesco, Sacchetti, Sciulli, Patrignani (bib7) 2007; 82 Greenblatt, von Moltke, Perloff, Luo, Harmatz, Zinny (bib12) 2006; 79 Lukaczer, Darland, Tripp, Liska, Lerman, Schiltz, Bland (bib27) 2005; 19 Verzele, De Keukeleire (bib45) 1991 Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J., 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520–1528 (1522 page following 1528). Lanas, Garcia-Rodriguez, Arroyo, Gomollon, Feu, Gonzalez-Perez, Zapata, Bastida, Rodrigo, Santolaria, Guell, de Argila, Quintero, Borda, Pique (bib26) 2006; 55 Holbrook, Pereira, Labiris, McDonald, Douketis, Crowther, Wells (bib19) 2005; 165 Minich, Bland, Katke, Darland, Hall, Lerman, Lamb, Tripp (bib31) 2007; 85 Dubois, Abramson, Crofford, Gupta, Simon, Van De Putte, Lipsky (bib10) 1998; 12 Hernandez-Diaz, Varas-Lorenzo, Garcia Rodriguez (bib17) 2006; 98 James, Cleland (bib22) 2006; 9 Laine, Connors, Reicin, Hawkey, Burgos-Vargas, Schnitzer, Yu, Bombardier (bib25) 2003; 124 Peura (bib37) 2004; 117 Ouellet, Falgueyret, Percival (bib36) 2004; 377 Friden, Vanaja, Nandi (bib11) 2006; 21 Hall, Tripp, Howell, Darland, Bland, Babish (bib15) 2006; 75 Nord, Sorensen, Duus (bib33) 2003; 41 McGettigan, Henry (bib29) 2006; 296 Murakami, Kambe, Shimbara, Kudo (bib32) 1999; 274 Holtzman, Turk, Shornick (bib20) 1992; 267 Bresalier, Sandler, Quan, Bolognese, Oxenius, Horgan, Lines, Riddell, Morton, Lanas, Konstam, Baron (bib6) 2005; 352 Vane, Bakhle, Botting (bib43) 1998; 38 Tibble, Sigthorsson, Foster, Scott, Fagerhol, Roseth, Bjarnason (bib40) 1999; 45 McAdam, Catella-Lawson, Mardini, Kapoor, Lawson, FitzGerald (bib28) 1999; 96 Meling, Aabakken, Roseth, Osnes (bib30) 1996; 31 Grosser, Fries, Fitzgerald (bib13) 2006; 116 Arroyo, Lanas (bib2) 2006; 52 Chandrasekharan, Dai, Roos, Evanson, Tomsik, Elton, Simmons (bib8) 2002; 99 Nozawa, Nakao, Zhao, Kondo (bib34) 2005; 49 Guengerich (bib14) 2003; 3 Konikoff, Denson (bib23) 2006; 12 Davidge (bib9) 2001; 89 Poullis, Foster, Mendall, Fagerhol (bib38) 2003; 18 Hla, Neilson (bib18) 1992; 89 Institute of Laboratory Animal Research, C.o.L.S., National Research Council, 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC. Yamamoto, Wang, Yamamoto, Tobe (bib46) 2000; 465 Monograph. Altern. Med. Rev. 8, 190–192. Bellamy, Buchanan, Goldsmith, Campbell, Stitt (bib3) 1988; 15 Hehner, Hofmann, Droge, Schmitz (bib16) 1999; 163 Verzele (10.1016/j.phytochem.2008.02.001_bib45) 1991 Hall (10.1016/j.phytochem.2008.02.001_bib15) 2006; 75 Vane (10.1016/j.phytochem.2008.02.001_bib43) 1998; 38 Kramer (10.1016/j.phytochem.2008.02.001_bib24) 1986; 19 Lukaczer (10.1016/j.phytochem.2008.02.001_bib27) 2005; 19 Meling (10.1016/j.phytochem.2008.02.001_bib30) 1996; 31 Yamamoto (10.1016/j.phytochem.2008.02.001_bib46) 2000; 465 Minich (10.1016/j.phytochem.2008.02.001_bib31) 2007; 85 Arroyo (10.1016/j.phytochem.2008.02.001_bib2) 2006; 52 Guengerich (10.1016/j.phytochem.2008.02.001_bib14) 2003; 3 Hla (10.1016/j.phytochem.2008.02.001_bib18) 1992; 89 Tibble (10.1016/j.phytochem.2008.02.001_bib40) 1999; 45 Dubois (10.1016/j.phytochem.2008.02.001_bib10) 1998; 12 Hernandez-Diaz (10.1016/j.phytochem.2008.02.001_bib17) 2006; 98 Bellamy (10.1016/j.phytochem.2008.02.001_bib3) 1988; 15 Bresalier (10.1016/j.phytochem.2008.02.001_bib6) 2005; 352 Capone (10.1016/j.phytochem.2008.02.001_bib7) 2007; 82 10.1016/j.phytochem.2008.02.001_bib4 McAdam (10.1016/j.phytochem.2008.02.001_bib28) 1999; 96 Laine (10.1016/j.phytochem.2008.02.001_bib25) 2003; 124 Chandrasekharan (10.1016/j.phytochem.2008.02.001_bib8) 2002; 99 Holtzman (10.1016/j.phytochem.2008.02.001_bib20) 1992; 267 Konikoff (10.1016/j.phytochem.2008.02.001_bib23) 2006; 12 Holbrook (10.1016/j.phytochem.2008.02.001_bib19) 2005; 165 Vanegas (10.1016/j.phytochem.2008.02.001_bib44) 2001; 64 Brater (10.1016/j.phytochem.2008.02.001_bib5) 2001; 21 Murakami (10.1016/j.phytochem.2008.02.001_bib32) 1999; 274 Lanas (10.1016/j.phytochem.2008.02.001_bib26) 2006; 55 Nussmeier (10.1016/j.phytochem.2008.02.001_bib35) 2005; 352 Solomon (10.1016/j.phytochem.2008.02.001_bib39) 2006; 114 Ouellet (10.1016/j.phytochem.2008.02.001_bib36) 2004; 377 Poullis (10.1016/j.phytochem.2008.02.001_bib38) 2003; 18 Hehner (10.1016/j.phytochem.2008.02.001_bib16) 1999; 163 Friden (10.1016/j.phytochem.2008.02.001_bib11) 2006; 21 McGettigan (10.1016/j.phytochem.2008.02.001_bib29) 2006; 296 Greenblatt (10.1016/j.phytochem.2008.02.001_bib12) 2006; 79 Nozawa (10.1016/j.phytochem.2008.02.001_bib34) 2005; 49 Topper (10.1016/j.phytochem.2008.02.001_bib41) 1996; 93 Davidge (10.1016/j.phytochem.2008.02.001_bib9) 2001; 89 Grosser (10.1016/j.phytochem.2008.02.001_bib13) 2006; 116 Nord (10.1016/j.phytochem.2008.02.001_bib33) 2003; 41 10.1016/j.phytochem.2008.02.001_bib1 Peura (10.1016/j.phytochem.2008.02.001_bib37) 2004; 117 10.1016/j.phytochem.2008.02.001_bib42 10.1016/j.phytochem.2008.02.001_bib21 James (10.1016/j.phytochem.2008.02.001_bib22) 2006; 9 |
| References_xml | – reference: . Monograph. Altern. Med. Rev. 8, 190–192. – volume: 98 start-page: 266 year: 2006 end-page: 274 ident: bib17 article-title: Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction publication-title: Basic Clin. Pharmacol. Toxicol. – volume: 114 start-page: 1028 year: 2006 end-page: 1035 ident: bib39 article-title: Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas publication-title: Circulation – volume: 21 start-page: 1 year: 2001 end-page: 15 ident: bib5 article-title: Renal effects of COX-2-selective inhibitors publication-title: Am. J. Nephrol. – volume: 12 start-page: 1063 year: 1998 end-page: 1073 ident: bib10 article-title: Cyclooxygenase in biology and disease publication-title: FASEB J. – volume: 45 start-page: 362 year: 1999 end-page: 366 ident: bib40 article-title: High prevalence of NSAID enteropathy as shown by a simple faecal test publication-title: Gut – volume: 15 start-page: 1833 year: 1988 end-page: 1840 ident: bib3 article-title: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee publication-title: J. Rheumatol. – volume: 89 start-page: 7384 year: 1992 end-page: 7388 ident: bib18 article-title: Human cyclooxygenase-2 cDNA publication-title: Proc. Natl. Acad. Sci. USA – volume: 82 start-page: 85 year: 2007 end-page: 94 ident: bib7 article-title: Pharmacodynamic of cyclooxygenase inhibitors in humans publication-title: Prostagland. Other Lipid Mediat. – volume: 165 start-page: 1095 year: 2005 end-page: 1106 ident: bib19 article-title: Systematic overview of warfarin and its drug and food interactions publication-title: Arch. Intern. Med. – volume: 79 start-page: 125 year: 2006 end-page: 133 ident: bib12 article-title: Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies publication-title: Clin. Pharmacol. Ther. – reference: Anonymous, 2003. – volume: 89 start-page: 650 year: 2001 end-page: 660 ident: bib9 article-title: Prostaglandin H synthase and vascular function publication-title: Circ. Res. – year: 1991 ident: bib45 article-title: Chemistry and Analysis of Hop and Beer Bitter Acids – reference: Institute of Laboratory Animal Research, C.o.L.S., National Research Council, 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC. – reference: Tripp, M., Babish, J., Darland, G., Lerman, R., Lukaczer, D., Schiltz, B., Bland, J., 2004. Hop and modified hop extracts have potent in vitro anti-inflammatory properties. In: Proceedings of the First ISHS International Humulus Symposium, Corvallis, OR, USA. – volume: 352 start-page: 1092 year: 2005 end-page: 1102 ident: bib6 article-title: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial publication-title: N. Engl. J. Med. – volume: 116 start-page: 4 year: 2006 end-page: 15 ident: bib13 article-title: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities publication-title: J. Clin. Invest. – volume: 96 start-page: 272 year: 1999 end-page: 277 ident: bib28 article-title: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 publication-title: Proc. Natl. Acad. Sci. USA – volume: 377 start-page: 675 year: 2004 end-page: 684 ident: bib36 article-title: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms publication-title: Biochem. J. – volume: 55 start-page: 1731 year: 2006 end-page: 1738 ident: bib26 article-title: Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations publication-title: Gut – volume: 3 start-page: 194 year: 2003 end-page: 204 ident: bib14 article-title: Cytochromes P450, drugs, and diseases publication-title: Mol. Interv. – volume: 93 start-page: 10417 year: 1996 end-page: 10422 ident: bib41 article-title: Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress publication-title: Proc. Natl. Acad. Sci. USA – volume: 64 start-page: 327 year: 2001 end-page: 363 ident: bib44 article-title: Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord publication-title: Prog. Neurobiol. – volume: 12 start-page: 524 year: 2006 end-page: 534 ident: bib23 article-title: Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease publication-title: Inflamm. Bowel Dis. – volume: 352 start-page: 1081 year: 2005 end-page: 1091 ident: bib35 article-title: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery publication-title: N. Engl. J. Med. – reference: Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J., 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520–1528 (1522 page following 1528). – volume: 267 start-page: 21438 year: 1992 end-page: 21445 ident: bib20 article-title: Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells publication-title: J. Biol. Chem. – volume: 75 start-page: 9 year: 2006 end-page: 17 ident: bib15 article-title: Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs publication-title: Prostagland. Leukot. Essent. Fatty Acid – volume: 296 start-page: 1633 year: 2006 end-page: 1644 ident: bib29 article-title: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 publication-title: JAMA – volume: 31 start-page: 339 year: 1996 end-page: 344 ident: bib30 article-title: Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs publication-title: Scand. J. Gastroenterol. – volume: 38 start-page: 97 year: 1998 end-page: 120 ident: bib43 article-title: Cyclooxygenases 1 and 2 publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 465 start-page: 103 year: 2000 end-page: 106 ident: bib46 article-title: Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid publication-title: FEBS Lett. – volume: 52 start-page: 249 year: 2006 end-page: 259 ident: bib2 article-title: NSAIDs-induced gastrointestinal damage publication-title: Rev. Miner. Gastroenterol. Dietol. – volume: 9 start-page: 89 year: 2006 end-page: 94 ident: bib22 article-title: Cyclooxygenase-2 inhibitors: what went wrong? publication-title: Curr. Opin. Clin. Nutr. Metab. Care – volume: 19 start-page: 225 year: 1986 end-page: 236 ident: bib24 article-title: The toxicology of non-narcotic analgesics publication-title: Agent Action Suppl. – volume: 21 start-page: 163 year: 2006 end-page: 185 ident: bib11 article-title: Drug–drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery publication-title: Drug Metabol. Drug Interact. – volume: 99 start-page: 13926 year: 2002 end-page: 13931 ident: bib8 article-title: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression publication-title: Proc. Natl. Acad. Sci. USA – volume: 124 start-page: 288 year: 2003 end-page: 292 ident: bib25 article-title: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use publication-title: Gastroenterology – volume: 85 start-page: 872 year: 2007 end-page: 883 ident: bib31 article-title: Clinical safety and efficacy of NG440: a novel, synergistic combination of rho publication-title: Can. J. Physiol. Pharmacol. – volume: 18 start-page: 756 year: 2003 end-page: 762 ident: bib38 article-title: Emerging role of calprotectin in gastroenterology publication-title: J. Gastroenterol. Hepatol. – volume: 19 start-page: 864 year: 2005 end-page: 869 ident: bib27 article-title: A pilot trial evaluating Meta050, a proprietary combination of reduced publication-title: Phytother. Res. – volume: 274 start-page: 3103 year: 1999 end-page: 3115 ident: bib32 article-title: Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways publication-title: J. Biol. Chem. – volume: 41 start-page: 660 year: 2003 end-page: 670 ident: bib33 article-title: Characterization of reduced publication-title: Magn. Reson. Chem. – volume: 49 start-page: 772 year: 2005 end-page: 778 ident: bib34 article-title: Dietary supplement of isohumulones inhibits the formation of aberrant crypt foci with a concomitant decrease in prostaglandin E2 level in rat colon publication-title: Mol. Nutr. Food Res. – volume: 117 start-page: 63S year: 2004 end-page: 71S ident: bib37 article-title: Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications publication-title: Am. J. Med. – volume: 163 start-page: 5617 year: 1999 end-page: 5623 ident: bib16 article-title: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex publication-title: J. Immunol. – volume: 352 start-page: 1081 year: 2005 ident: 10.1016/j.phytochem.2008.02.001_bib35 article-title: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa050330 – volume: 19 start-page: 864 year: 2005 ident: 10.1016/j.phytochem.2008.02.001_bib27 article-title: A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia publication-title: Phytother. Res. doi: 10.1002/ptr.1709 – volume: 89 start-page: 650 year: 2001 ident: 10.1016/j.phytochem.2008.02.001_bib9 article-title: Prostaglandin H synthase and vascular function publication-title: Circ. Res. doi: 10.1161/hh2001.098351 – volume: 45 start-page: 362 year: 1999 ident: 10.1016/j.phytochem.2008.02.001_bib40 article-title: High prevalence of NSAID enteropathy as shown by a simple faecal test publication-title: Gut doi: 10.1136/gut.45.3.362 – ident: 10.1016/j.phytochem.2008.02.001_bib42 doi: 10.17660/ActaHortic.2005.668.28 – volume: 21 start-page: 1 year: 2001 ident: 10.1016/j.phytochem.2008.02.001_bib5 article-title: Renal effects of COX-2-selective inhibitors publication-title: Am. J. Nephrol. doi: 10.1159/000046212 – volume: 89 start-page: 7384 year: 1992 ident: 10.1016/j.phytochem.2008.02.001_bib18 article-title: Human cyclooxygenase-2 cDNA publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.89.16.7384 – ident: 10.1016/j.phytochem.2008.02.001_bib1 doi: 10.1029/2003EO200008 – volume: 114 start-page: 1028 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib39 article-title: Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.636746 – volume: 296 start-page: 1633 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib29 article-title: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 publication-title: JAMA doi: 10.1001/jama.296.13.jrv60011 – volume: 31 start-page: 339 year: 1996 ident: 10.1016/j.phytochem.2008.02.001_bib30 article-title: Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs publication-title: Scand. J. Gastroenterol. doi: 10.3109/00365529609006407 – ident: 10.1016/j.phytochem.2008.02.001_bib4 doi: 10.1056/NEJM200011233432103 – volume: 117 start-page: 63S issue: Suppl. 5A year: 2004 ident: 10.1016/j.phytochem.2008.02.001_bib37 article-title: Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications publication-title: Am. J. Med. – volume: 15 start-page: 1833 year: 1988 ident: 10.1016/j.phytochem.2008.02.001_bib3 article-title: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee publication-title: J. Rheumatol. – volume: 75 start-page: 9 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib15 article-title: Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs publication-title: Prostagland. Leukot. Essent. Fatty Acid doi: 10.1016/j.plefa.2006.04.006 – volume: 267 start-page: 21438 year: 1992 ident: 10.1016/j.phytochem.2008.02.001_bib20 article-title: Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(19)36629-3 – volume: 352 start-page: 1092 year: 2005 ident: 10.1016/j.phytochem.2008.02.001_bib6 article-title: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa050493 – volume: 55 start-page: 1731 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib26 article-title: Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations publication-title: Gut doi: 10.1136/gut.2005.080754 – volume: 96 start-page: 272 year: 1999 ident: 10.1016/j.phytochem.2008.02.001_bib28 article-title: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.96.1.272 – volume: 165 start-page: 1095 year: 2005 ident: 10.1016/j.phytochem.2008.02.001_bib19 article-title: Systematic overview of warfarin and its drug and food interactions publication-title: Arch. Intern. Med. doi: 10.1001/archinte.165.10.1095 – volume: 19 start-page: 225 year: 1986 ident: 10.1016/j.phytochem.2008.02.001_bib24 article-title: The toxicology of non-narcotic analgesics publication-title: Agent Action Suppl. – volume: 99 start-page: 13926 year: 2002 ident: 10.1016/j.phytochem.2008.02.001_bib8 article-title: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.162468699 – volume: 85 start-page: 872 year: 2007 ident: 10.1016/j.phytochem.2008.02.001_bib31 article-title: Clinical safety and efficacy of NG440: a novel, synergistic combination of rho iso-alpha acids from hops, rosemary and oleanolic acid for inflammatory conditions publication-title: Can. J. Physiol. Pharmacol. doi: 10.1139/Y07-055 – volume: 93 start-page: 10417 year: 1996 ident: 10.1016/j.phytochem.2008.02.001_bib41 article-title: Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.93.19.10417 – volume: 52 start-page: 249 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib2 article-title: NSAIDs-induced gastrointestinal damage publication-title: Rev. Miner. Gastroenterol. Dietol. – volume: 49 start-page: 772 year: 2005 ident: 10.1016/j.phytochem.2008.02.001_bib34 article-title: Dietary supplement of isohumulones inhibits the formation of aberrant crypt foci with a concomitant decrease in prostaglandin E2 level in rat colon publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.200500027 – volume: 12 start-page: 524 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib23 article-title: Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease publication-title: Inflamm. Bowel Dis. doi: 10.1097/00054725-200606000-00013 – volume: 41 start-page: 660 year: 2003 ident: 10.1016/j.phytochem.2008.02.001_bib33 article-title: Characterization of reduced iso-alpha-acids derived from hops (Humulus lupulus) by NMR publication-title: Magn. Reson. Chem. doi: 10.1002/mrc.1234 – volume: 465 start-page: 103 year: 2000 ident: 10.1016/j.phytochem.2008.02.001_bib46 article-title: Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid publication-title: FEBS Lett. doi: 10.1016/S0014-5793(99)01727-5 – volume: 3 start-page: 194 year: 2003 ident: 10.1016/j.phytochem.2008.02.001_bib14 article-title: Cytochromes P450, drugs, and diseases publication-title: Mol. Interv. doi: 10.1124/mi.3.4.194 – ident: 10.1016/j.phytochem.2008.02.001_bib21 – volume: 124 start-page: 288 year: 2003 ident: 10.1016/j.phytochem.2008.02.001_bib25 article-title: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use publication-title: Gastroenterology doi: 10.1053/gast.2003.50054 – volume: 98 start-page: 266 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib17 article-title: Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction publication-title: Basic Clin. Pharmacol. Toxicol. doi: 10.1111/j.1742-7843.2006.pto_302.x – volume: 21 start-page: 163 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib11 article-title: Drug–drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery publication-title: Drug Metabol. Drug Interact. doi: 10.1515/DMDI.2006.21.3-4.163 – volume: 9 start-page: 89 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib22 article-title: Cyclooxygenase-2 inhibitors: what went wrong? publication-title: Curr. Opin. Clin. Nutr. Metab. Care doi: 10.1097/01.mco.0000214565.67439.83 – volume: 82 start-page: 85 year: 2007 ident: 10.1016/j.phytochem.2008.02.001_bib7 article-title: Pharmacodynamic of cyclooxygenase inhibitors in humans publication-title: Prostagland. Other Lipid Mediat. doi: 10.1016/j.prostaglandins.2006.05.019 – volume: 79 start-page: 125 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib12 article-title: Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies publication-title: Clin. Pharmacol. Ther. doi: 10.1016/j.clpt.2005.09.014 – volume: 38 start-page: 97 year: 1998 ident: 10.1016/j.phytochem.2008.02.001_bib43 article-title: Cyclooxygenases 1 and 2 publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.38.1.97 – volume: 116 start-page: 4 year: 2006 ident: 10.1016/j.phytochem.2008.02.001_bib13 article-title: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities publication-title: J. Clin. Invest. doi: 10.1172/JCI27291 – year: 1991 ident: 10.1016/j.phytochem.2008.02.001_bib45 – volume: 18 start-page: 756 year: 2003 ident: 10.1016/j.phytochem.2008.02.001_bib38 article-title: Emerging role of calprotectin in gastroenterology publication-title: J. Gastroenterol. Hepatol. doi: 10.1046/j.1440-1746.2003.03014.x – volume: 64 start-page: 327 year: 2001 ident: 10.1016/j.phytochem.2008.02.001_bib44 article-title: Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord publication-title: Prog. Neurobiol. doi: 10.1016/S0301-0082(00)00063-0 – volume: 274 start-page: 3103 year: 1999 ident: 10.1016/j.phytochem.2008.02.001_bib32 article-title: Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways publication-title: J. Biol. Chem. doi: 10.1074/jbc.274.5.3103 – volume: 377 start-page: 675 year: 2004 ident: 10.1016/j.phytochem.2008.02.001_bib36 article-title: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms publication-title: Biochem. J. doi: 10.1042/bj20030969 – volume: 12 start-page: 1063 year: 1998 ident: 10.1016/j.phytochem.2008.02.001_bib10 article-title: Cyclooxygenase in biology and disease publication-title: FASEB J. doi: 10.1096/fasebj.12.12.1063 – volume: 163 start-page: 5617 year: 1999 ident: 10.1016/j.phytochem.2008.02.001_bib16 article-title: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex publication-title: J. Immunol. doi: 10.4049/jimmunol.163.10.5617 |
| SSID | ssj0005566 |
| Score | 2.1010137 |
| Snippet | Rho
iso-alpha-acids (RIAA) is a modified extract from the flower cone of hops (
Humulus lupulus L.). The safety profile and anti-inflammatory activity of RIAA... A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. RIAA inhibited LPS-stimulated... |
| SourceID | proquest pubmed pascalfrancis crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1534 |
| SubjectTerms | Adult adverse effects Aged Alkanes Alkanes - adverse effects Alkanes - pharmacokinetics Alkanes - therapeutic use Animals Anti-inflammatory anti-inflammatory activity Anti-Inflammatory Agents Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - pharmacokinetics Anti-Inflammatory Agents - therapeutic use Biological and medical sciences Biological Availability blood chemistry blood pressure Body Weight Body Weight - drug effects Calprotectin Cannabidaceae Cell Line Chemical constitution chemistry Chromatography, Liquid cultured cells Cyclooxygenase Cyclooxygenase Inhibitors Cyclooxygenase Inhibitors - adverse effects Cyclooxygenase Inhibitors - pharmacokinetics Cyclooxygenase Inhibitors - therapeutic use Cyclopentanes Cyclopentanes - adverse effects Cyclopentanes - pharmacokinetics Cyclopentanes - therapeutic use drug effects enzyme activity Feces Feces - chemistry Female Fundamental and applied biological sciences. Psychology General pharmacology Hops Humans Humulus Humulus - chemistry Humulus lupulus Humulus lupulus L Kidney Kidney - drug effects Kidney - pathology Knee osteoarthritis Leukocyte L1 Antigen Complex Leukocyte L1 Antigen Complex - metabolism Liver Liver - drug effects Liver - pathology Male Mass Spectrometry Medical sciences metabolism Mice Middle Aged NSAID Organ Size Organ Size - drug effects osteoarthritis Osteoarthritis - pathology Osteoarthritis - prevention & control pathology PGE 2 Pharmacognosy. Homeopathy. Health food pharmacokinetics Pharmacology. Drug treatments phytochemicals Plant Extracts Plant Extracts - adverse effects Plant Extracts - pharmacokinetics Plant Extracts - therapeutic use Plant physiology and development prevention & control Prostaglandin prostaglandin synthase prostaglandins Prostaglandins - urine Rho iso-alpha-acids therapeutic use Treatment Outcome urine |
| Title | Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops |
| URI | https://dx.doi.org/10.1016/j.phytochem.2008.02.001 https://www.ncbi.nlm.nih.gov/pubmed/18358504 https://www.proquest.com/docview/47697629 https://www.proquest.com/docview/69129943 |
| Volume | 69 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZK4cAF8W54LD5wJDRxbCfhViqqhRUVoqzozfKzDaLJqkkPe-G3M5PHwh5KDxyiSJEt-TGeb-L5ZoaQ16DyAOXgJycNhY15mppYMws_riJ1zJYyNxbvIT8fy_mSfzoVpzvkcIqFQVrlqPsHnd5r6_HL_ria-6uqwhhfEB_OGNo8AHwYUc55jvnz3_76i-YhBn8lNI6x9RbHC2bSYWGqi5FUick70-sQ6lbQDVIndQurF4ayF9fbpT0-Hd0n90bDkh4MY39Adnz9kNx534Dxt35Evpzo4Lv1G-oxZYS2a6prB09XxSBiIBUXvbedYpgDVpOgTaCX5w2t2ibuw3FjbSvXUoxGoefNqn1Mlkcfvh3O47GYQmy54F3skuCyxDsdXAHAhd5IGaTzPrFpoU2hg5Q5wLnOrcwlN14KY1NjbRFMKUKZPSG7dVP7PUKFSwH3jBOJyQDgXQFdjZC55pbpjPuIyGkBlR0zjWPBi59qopT9UJuVH-tgMiTXRSTZdFwNyTZu7vJu2iG1JTcKIOHmznuwp0qfgT5VyxOGXtykKJlgPCKzrY3ejIclWYZXPxF5Ne28ghOJbhZd--aqVTyXYOOxf7SQJVhZJc8i8nQQmT-zBYO4EAl_9j_Tek7uDqwWpGW-ILvd5ZV_CaZTZ2b92ZiR2wcfF_NjfC--fl_8BpoQGNw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELbagkQviHdToPWBI6GJYzsJN6ioFmgrpHal3iw_aRBNVk162Au_nZk8FvZQeuCQS2RLtmc839jzjYeQN2DyAOXgkJOGwsY8TU2smYWDq0gds6XMjcV7yJNTOZvzLxfiYoMcTrkwSKscbf9g03trPf45GFfzYFFVmOML6sMZQ58HgC_fJPe4yHJU7Xe__uJ5iCFgCa1jbL5G8oKpdFiZ6mpkVeLrneltELUZdIPcSd3C8oWh7sXtjmkPUEePyMPRs6QfhsE_Jhu-fkLuf2zA-1s-Jd_OdPDd8i31-GaEtkuqawdfV8WgY6AWV324nWKeA5aToE2g15cNrdom7vNxY20r11JMR6GXzaJ9RuZHn84PZ_FYTSG2XPAudklwWeKdDq4A5MJwpAzSeZ_YtNCm0EHKHPBc51bmkhsvhbGpsbYIphShzJ6Trbqp_Q6hwqUAfMaJxGSA8K6ArkbIXHPLdMZ9ROS0gMqOT41jxYufauKU_VCrlR8LYTJk10UkWXVcDK9t3N3l_SQhtaY4CjDh7s47IFOlv4NBVfMzhmHcpCiZYDwie2uCXo2HJVmGdz8R2Z8kr2BLYpxF1765aRXPJTh57B8tZAluVsmziLwYVObPbMEjLkTCd_9nWvvkwez85Fgdfz79-pJsDxQX5Gi-Ilvd9Y1_DX5UZ_b6ffIbKScYzw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+efficacy+and+anti-inflammatory+activity+of+rho+iso-alpha-acids+from+hops&rft.jtitle=Phytochemistry+%28Oxford%29&rft.au=Hall%2C+Amy+J.&rft.au=Babish%2C+John+G.&rft.au=Darland%2C+Gary+K.&rft.au=Carroll%2C+Brian+J.&rft.date=2008-05-01&rft.pub=Elsevier+Ltd&rft.issn=0031-9422&rft.eissn=1873-3700&rft.volume=69&rft.issue=7&rft.spage=1534&rft.epage=1547&rft_id=info:doi/10.1016%2Fj.phytochem.2008.02.001&rft.externalDocID=S0031942208000757 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-9422&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-9422&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-9422&client=summon |